US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

OPUS GENETICS INC

4.33

+0.17004.09%

Post-market: 4.330.00000.00%19:45 EST

Volume:1.28M

Turnover:5.37M

Market Cap:298.62M

PE:-2.33

High:4.42

Open:4.08

Low:3.83

Close:4.16

52wk High:4.42

52wk Low:0.6500

Shares:68.96M

Float Shares:63.12M

Volume Ratio:1.43

T/O Rate:2.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.8600

EPS(LYR):-2.1535

ROE:-338.75%

ROA:-60.73%

PB:50.04

PE(LYR):-2.01

Loading ...

Overview Company News Filings

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Opus Genetics Gene Therapy Restores Partial Sight in Inherited Blindness Trial

Opus Genetics Initiated at Outperform by Wedbush

Opus Genetics Initiated at Buy by Chardan Capital

Opus Genetics Inc. to Present Corporate Update at Chardan's 9th Annual Genetic Medicines Conference

Opus Genetics Announces Positive Clinical Trial Results for Gene Therapy and Phentolamine Ophthalmic Solution, Plans Key Data Presentations in October 2025

Opus Genetics Announces Positive Pediatric Data from OPGx-LCA5 Gene Therapy Trial for Leber Congenital Amaurosis Type 5; FDA Meeting Expected in Q4 2025

Opus Genetics Inc - Opgx-Lca5 Well-Tolerated in All Participants

THOMSON REUTERS

Opus Genetics Reports Positive Pediatric Data From Opgx-Lca5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (Lca5)

THOMSON REUTERS

Opus Genetics reports inducement grant under Nasdaq listing rules

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Opus Genetics Inc. Files Initial Beneficial Ownership Statement for CFO Robert E. Gagnon

Opus Genetics Announces Dosing of First Patient in Phase 3 Trial of Phentolamine Ophthalmic Solution for Night Vision Disturbances

Opus Genetics Doses First Patient in Pivotal Lynx-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IRD/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","market":"US","secType":"STK","nameCN":"OPUS GENETICS INC","latestPrice":4.33,"timestamp":1772485200000,"preClose":4.16,"halted":0,"volume":1282294,"hourTrading":{"tag":"盘后","latestPrice":4.33,"preClose":4.33,"latestTime":"19:45 EST","volume":19431,"amount":84126.5957,"timestamp":1772498723108,"change":0,"changeRate":0,"amplitude":0.006928},"delay":0,"changeRate":0.040865384615384595,"floatShares":63122173,"shares":68964208,"eps":-1.86,"marketStatus":"Not Yet Opened","change":0.17,"latestTime":"03-02 16:00:00 EST","open":4.08,"high":4.42,"low":3.8306,"amount":5365930.6857078,"amplitude":0.141683,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.86,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772528400000},"marketStatusCode":0,"adr":0,"listingDate":1100235600000,"exchange":"NASDAQ","adjPreClose":4.16,"preHourTrading":{"tag":"盘前","latestPrice":4.12,"preClose":4.16,"latestTime":"09:29 EST","volume":19418,"amount":75190.49610799999,"timestamp":1772461799417,"change":-0.04,"changeRate":-0.009615,"amplitude":0.105769},"postHourTrading":{"tag":"盘后","latestPrice":4.33,"preClose":4.33,"latestTime":"19:45 EST","volume":19431,"amount":84126.5957,"timestamp":1772498723108,"change":0,"changeRate":0,"amplitude":0.006928},"volumeRatio":1.431301,"impliedVol":2.2914,"impliedVolPercentile":0.9761},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","floatShares":63122173,"roa":"-60.73%","roe":"-338.75%","lyrEps":-2.153504,"volumeRatio":1.431301,"shares":68964208,"dividePrice":0,"high":4.42,"amplitude":0.141683,"preClose":4.16,"low":3.8306,"week52Low":0.65,"pbRate":"50.04","psRate":"20.41","week52High":4.42,"institutionHeld":0,"latestPrice":4.33,"eps":-1.86,"divideRate":0,"volume":1282294,"delay":0,"ttmEps":-1.86,"open":4.08,"prevYearClose":2.01,"prevWeekClose":4.16,"prevMonthClose":4.16,"prevQuarterClose":2.01,"fiveDayClose":3.45,"twentyDayClose":2.31,"sixtyDayClose":1.99},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"IRD","fiscalQuarterEnding":"2025/09","expectedEps":-0.14,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.12},{"market":"US","date":"2025-08-13","symbol":"IRD","fiscalQuarterEnding":"2025/06","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.12},{"market":"US","date":"2025-05-15","symbol":"IRD","fiscalQuarterEnding":"2025/03","expectedEps":-0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.32},{"market":"US","date":"2025-03-31","symbol":"IRD","fiscalQuarterEnding":"2024/12","expectedEps":-0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":-1.27},{"market":"US","date":"2024-11-12","symbol":"IRD","fiscalQuarterEnding":"2024/09","expectedEps":-0.3,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.29}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.8333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":12,"updateTime":1772254800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IRD","date":"2026-02-27","current":-2.327957,"percent":0.012048,"low":-3.933416,"twenty":-2.153773,"median":-1.330709,"eighty":-1.044184,"high":-0.560128,"avg":-1.579118,"sd":0.69548,"marketCap":247581506},"quantilePoints":[{"date":"2024-10-31","current":-2.785848,"twenty":-2.857166,"median":-2.64666,"eighty":-2.37374,"marketCap":39294383},{"date":"2024-11-08","current":-2.429259,"twenty":-2.692243,"median":-2.607554,"eighty":-2.476187,"marketCap":34264702},{"date":"2024-11-15","current":-1.225421,"twenty":-2.616468,"median":-2.568551,"eighty":-2.326813,"marketCap":33321637},{"date":"2024-11-22","current":-1.142487,"twenty":-2.607554,"median":-2.49612,"eighty":-1.192247,"marketCap":31066518},{"date":"2024-11-29","current":-1.288651,"twenty":-2.607554,"median":-2.173143,"eighty":-1.193702,"marketCap":35040987},{"date":"2024-12-06","current":-1.323479,"twenty":-2.603096,"median":-1.364112,"eighty":-1.225421,"marketCap":35988040},{"date":"2024-12-13","current":-1.288651,"twenty":-2.574123,"median":-1.335088,"eighty":-1.234669,"marketCap":35040987},{"date":"2024-12-20","current":-1.14597,"twenty":-2.527405,"median":-1.303163,"eighty":-1.16559,"marketCap":31161223},{"date":"2024-12-27","current":-1.253822,"twenty":-2.505202,"median":-1.288651,"eighty":-1.163268,"marketCap":34093933},{"date":"2025-01-03","current":-1.462793,"twenty":-2.49612,"median":-1.294455,"eighty":-1.172556,"marketCap":39776255},{"date":"2025-01-10","current":-1.683372,"twenty":-2.442631,"median":-1.320577,"eighty":-1.181843,"marketCap":45774262},{"date":"2025-01-17","current":-1.346698,"twenty":-2.224366,"median":-1.346698,"eighty":-1.20274,"marketCap":36619410},{"date":"2025-01-24","current":-1.335088,"twenty":-1.87928,"median":-1.335088,"eighty":-1.207384,"marketCap":36303725},{"date":"2025-01-31","current":-1.288651,"twenty":-1.676407,"median":-1.329284,"eighty":-1.218206,"marketCap":35040987},{"date":"2025-02-07","current":-1.416355,"twenty":-1.657832,"median":-1.323479,"eighty":-1.225421,"marketCap":38513517},{"date":"2025-02-14","current":-1.335088,"twenty":-1.648544,"median":-1.323479,"eighty":-1.239294,"marketCap":36303725},{"date":"2025-02-21","current":-1.288651,"twenty":-1.616038,"median":-1.323479,"eighty":-1.250654,"marketCap":35040987},{"date":"2025-02-28","current":-1.207384,"twenty":-1.525484,"median":-1.317674,"eighty":-1.232138,"marketCap":32831195},{"date":"2025-03-07","current":-1.160946,"twenty":-1.444218,"median":-1.31187,"eighty":-1.207384,"marketCap":31568457},{"date":"2025-03-14","current":-1.07968,"twenty":-1.411711,"median":-1.30026,"eighty":-1.1772,"marketCap":29358665},{"date":"2025-03-21","current":-1.335088,"twenty":-1.404745,"median":-1.30026,"eighty":-1.16559,"marketCap":36303725},{"date":"2025-03-28","current":-1.637559,"twenty":-1.525484,"median":-1.31187,"eighty":-1.1772,"marketCap":44528506},{"date":"2025-04-04","current":-0.76585,"twenty":-1.525484,"median":-1.306065,"eighty":-1.160946,"marketCap":44060874},{"date":"2025-04-11","current":-0.564318,"twenty":-1.462793,"median":-1.288651,"eighty":-1.14388,"marketCap":32466352},{"date":"2025-04-17","current":-0.581158,"twenty":-1.453505,"median":-1.288651,"eighty":-1.129154,"marketCap":33435158},{"date":"2025-04-25","current":-0.632466,"twenty":-1.414033,"median":-1.288651,"eighty":-1.081468,"marketCap":36387058},{"date":"2025-05-02","current":-0.741567,"twenty":-1.404745,"median":-1.288651,"eighty":-1.054291,"marketCap":42663825},{"date":"2025-05-09","current":-0.787263,"twenty":-1.404745,"median":-1.277041,"eighty":-0.791089,"marketCap":45292790},{"date":"2025-05-16","current":-0.737114,"twenty":-1.402423,"median":-1.253822,"eighty":-0.755291,"marketCap":43209631},{"date":"2025-05-23","current":-0.783669,"twenty":-1.393136,"median":-1.253822,"eighty":-0.759832,"marketCap":45938661},{"date":"2025-05-30","current":-0.771642,"twenty":-1.393136,"median":-1.251182,"eighty":-0.76585,"marketCap":45233661},{"date":"2025-06-06","current":-1.017762,"twenty":-1.393136,"median":-1.225421,"eighty":-0.767335,"marketCap":59661197},{"date":"2025-06-13","current":-1.009213,"twenty":-1.381526,"median":-1.207384,"eighty":-0.771254,"marketCap":59160042},{"date":"2025-06-20","current":-0.947842,"twenty":-1.372239,"median":-1.207384,"eighty":-0.771564,"marketCap":55562472},{"date":"2025-06-27","current":-1.038117,"twenty":-1.360629,"median":-1.184165,"eighty":-0.771642,"marketCap":60854420},{"date":"2025-07-03","current":-1.017762,"twenty":-1.358307,"median":-1.160946,"eighty":-0.77653,"marketCap":59661197},{"date":"2025-07-11","current":-1.139893,"twenty":-1.351342,"median":-1.160017,"eighty":-0.782117,"marketCap":66820540},{"date":"2025-07-18","current":-1.185692,"twenty":-1.346698,"median":-1.152239,"eighty":-0.783669,"marketCap":69505294},{"date":"2025-07-25","current":-1.231492,"twenty":-1.339732,"median":-1.160017,"eighty":-0.783669,"marketCap":72190048},{"date":"2025-08-01","current":-1.129716,"twenty":-1.335088,"median":-1.160248,"eighty":-0.785825,"marketCap":66223928},{"date":"2025-08-08","current":-1.10936,"twenty":-1.335088,"median":-1.151155,"eighty":-0.789762,"marketCap":65030704},{"date":"2025-08-15","current":-1.213067,"twenty":-1.335088,"median":-1.150071,"eighty":-0.791428,"marketCap":70691504},{"date":"2025-08-22","current":-1.177087,"twenty":-1.335088,"median":-1.151155,"eighty":-0.791428,"marketCap":68594722},{"date":"2025-08-29","current":-1.287434,"twenty":-1.335088,"median":-1.160248,"eighty":-0.791428,"marketCap":75025207},{"date":"2025-09-05","current":-1.384803,"twenty":-1.335088,"median":-1.160946,"eighty":-0.797415,"marketCap":80699383},{"date":"2025-09-12","current":-1.525447,"twenty":-1.342054,"median":-1.174821,"eighty":-0.822134,"marketCap":88895414},{"date":"2025-09-19","current":-1.611997,"twenty":-1.365273,"median":-1.182227,"eighty":-0.876364,"marketCap":93939125},{"date":"2025-09-26","current":-1.860829,"twenty":-1.384803,"median":-1.184928,"eighty":-0.929339,"marketCap":108439795},{"date":"2025-10-03","current":-1.947379,"twenty":-1.400101,"median":-1.195775,"eighty":-0.939944,"marketCap":113483507},{"date":"2025-10-10","current":-2.152936,"twenty":-1.42988,"median":-1.207384,"eighty":-0.94314,"marketCap":125462322},{"date":"2025-10-17","current":-2.174573,"twenty":-1.477844,"median":-1.207384,"eighty":-0.951343,"marketCap":126723249},{"date":"2025-10-24","current":-2.163754,"twenty":-1.521119,"median":-1.217191,"eighty":-0.957164,"marketCap":126092786},{"date":"2025-10-31","current":-2.131298,"twenty":-1.627334,"median":-1.225421,"eighty":-0.958345,"marketCap":124201394},{"date":"2025-11-07","current":-2.196211,"twenty":-1.661499,"median":-1.23256,"eighty":-0.960734,"marketCap":127984177},{"date":"2025-11-14","current":-2.001473,"twenty":-1.74585,"median":-1.242213,"eighty":-0.964942,"marketCap":116635827},{"date":"2025-11-21","current":-1.951541,"twenty":-1.828372,"median":-1.253822,"eighty":-0.975077,"marketCap":133100921},{"date":"2025-11-28","current":-2.153773,"twenty":-1.878321,"median":-1.253822,"eighty":-0.98727,"marketCap":146893763},{"date":"2025-12-05","current":-2.254889,"twenty":-1.925381,"median":-1.265432,"eighty":-0.988735,"marketCap":153790183},{"date":"2025-12-12","current":-2.467233,"twenty":-1.950709,"median":-1.277041,"eighty":-0.996674,"marketCap":168272667},{"date":"2025-12-19","current":-2.002099,"twenty":-2.002099,"median":-1.288651,"eighty":-1.007767,"marketCap":136549131},{"date":"2025-12-26","current":-2.062768,"twenty":-2.022322,"median":-1.288651,"eighty":-1.0085,"marketCap":140686984},{"date":"2026-01-02","current":-2.032433,"twenty":-2.02248,"median":-1.288651,"eighty":-1.00907,"marketCap":138618058},{"date":"2026-01-09","current":-2.022322,"twenty":-2.035652,"median":-1.288651,"eighty":-1.009619,"marketCap":137928416},{"date":"2026-01-16","current":-2.103215,"twenty":-2.062768,"median":-1.30026,"eighty":-1.016154,"marketCap":143445552},{"date":"2026-01-23","current":-2.527902,"twenty":-2.079519,"median":-1.303662,"eighty":-1.017762,"marketCap":172410520},{"date":"2026-01-30","current":-2.527902,"twenty":-2.105793,"median":-1.31187,"eighty":-1.017762,"marketCap":172410520},{"date":"2026-02-06","current":-2.608795,"twenty":-2.126582,"median":-1.317674,"eighty":-1.019861,"marketCap":177927656},{"date":"2026-02-13","current":-3.427836,"twenty":-2.136977,"median":-1.323479,"eighty":-1.031375,"marketCap":233788665},{"date":"2026-02-20","current":-3.609844,"twenty":-2.149226,"median":-1.323479,"eighty":-1.038117,"marketCap":246202222},{"date":"2026-02-27","current":-3.630068,"twenty":-2.153773,"median":-1.330709,"eighty":-1.044184,"marketCap":247581506}],"updateTime":1772500438494},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IRD\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2581766002","title":"Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581766002","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581766002?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:01","pubTimestamp":1762290064,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA8TYHD0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","IRD"],"gpt_icon":0},{"id":"2580653213","title":"Opus Genetics Gene Therapy Restores Partial Sight in Inherited Blindness Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2580653213","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580653213?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:01","pubTimestamp":1762174888,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc. was recently featured on Good Morning America for its pioneering work in developing gene therapies targeting inherited retinal diseases . The segment highlighted the story of Lindsey Rambo, the second participant in Opus Genetics' ongoing Phase 1/2 clinical trial of their investigational gene therapy OPGx-LCA5. This therapy aims to restore vision in individuals with a rare genetic form of blindness caused by mutations in the LCA5 gene. The therapy works by delivering a functional copy of the defective gene directly to retinal cells, with the goal of restoring the function of light-sensing photoreceptors. The news coverage brings attention to the promising early results and ongoing clinical trials, but no new research data or specific trial outcomes were formally announced or presented at this time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, thi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL9qSS8f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4007","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4585","IRD","LU2210150020.SGD","NDAQ","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2579150905","title":"Opus Genetics Initiated at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2579150905","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579150905?lang=en_us&edition=fundamental","pubTime":"2025-10-29 20:36","pubTimestamp":1761741360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 29, 2025 08:36 ET (12:36 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","BK4139"],"gpt_icon":0},{"id":"2575689749","title":"Opus Genetics Initiated at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2575689749","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575689749?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:46","pubTimestamp":1760618760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 16, 2025 08:46 ET (12:46 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IRD","BK4007"],"gpt_icon":0},{"id":"2575929772","title":"Opus Genetics Inc. to Present Corporate Update at Chardan's 9th Annual Genetic Medicines Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575929772","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575929772?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:00","pubTimestamp":1760443245,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc. will participate in Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025. Chief Scientific and Development Officer Ash Jayagopal will present a corporate update at the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire  on October 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL75lFCW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","LU2095319765.USD","BK4112","LU2210150020.SGD","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","NDAQ","BK4585","BK4007","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4588","LU0314104364.USD"],"gpt_icon":0},{"id":"2572851496","title":"Opus Genetics Announces Positive Clinical Trial Results for Gene Therapy and Phentolamine Ophthalmic Solution, Plans Key Data Presentations in October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2572851496","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572851496?lang=en_us&edition=fundamental","pubTime":"2025-10-02 20:00","pubTimestamp":1759406454,"startTime":"0","endTime":"0","summary":"Opus Genetics Announces Positive Clinical Trial Results for Gene Therapy and Phentolamine Ophthalmic Solution, Plans Key Data Presentations in October 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire  on October 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nNDL5DB8nH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","BK4588","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","NDAQ","BK4007","BK4139","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IRD","LU2095319765.USD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2571349482","title":"Opus Genetics Announces Positive Pediatric Data from OPGx-LCA5 Gene Therapy Trial for Leber Congenital Amaurosis Type 5; FDA Meeting Expected in Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2571349482","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571349482?lang=en_us&edition=fundamental","pubTime":"2025-09-30 19:00","pubTimestamp":1759230021,"startTime":"0","endTime":"0","summary":"Opus Genetics Announces Positive Pediatric Data from OPGx-LCA5 Gene Therapy Trial for Leber Congenital Amaurosis Type 5; FDA Meeting Expected in Q4 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire  on September 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDLbY2xYt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4007","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0314104364.USD","BK4588","NDAQ","LU2095319765.USD","IE00BKPKM429.USD","BK4585","BK4139","IRD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2571349178","title":"Opus Genetics Inc - Opgx-Lca5 Well-Tolerated in All Participants","url":"https://stock-news.laohu8.com/highlight/detail?id=2571349178","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571349178?lang=en_us&edition=fundamental","pubTime":"2025-09-30 19:00","pubTimestamp":1759230000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nTUAC7DYVW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007","BK4139"],"gpt_icon":0},{"id":"2571349123","title":"Opus Genetics Reports Positive Pediatric Data From Opgx-Lca5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (Lca5)","url":"https://stock-news.laohu8.com/highlight/detail?id=2571349123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571349123?lang=en_us&edition=fundamental","pubTime":"2025-09-30 19:00","pubTimestamp":1759230000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nTUAC7DYVW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IRD","BK4007"],"gpt_icon":0},{"id":"2566979492","title":"Opus Genetics reports inducement grant under Nasdaq listing rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2566979492","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566979492?lang=en_us&edition=fundamental","pubTime":"2025-09-12 20:10","pubTimestamp":1757679055,"startTime":"0","endTime":"0","summary":"Opus Genetics (IRD) announced that the Compensation Committee of its Board of Directors approved equity awards under the Company’s 2021 Inducement ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opus-genetics-reports-inducement-grant-under-nasdaq-listing-rules-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opus-genetics-reports-inducement-grant-under-nasdaq-listing-rules-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRD","LU0314104364.USD","IE00B3QW5Z07.USD","USAW.SI","IE00BGHQF748.EUR","NQmain","LU2095319765.USD","NDAQ","SQQQ","PSQ","USJW.SI",".IXIC","LU2210150020.SGD","BK4588","QID","TQQQ","NVIW.SI","BK4139","MNQmain","LU2210149790.SGD","BK4007","BK4112","TSYW.SI","IE00B64PRP62.GBP","BK4585","IE00BKPKM429.USD","QLD"],"gpt_icon":0},{"id":"2566976796","title":"Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2566976796","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566976796?lang=en_us&edition=fundamental","pubTime":"2025-09-12 20:00","pubTimestamp":1757678400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nTUA1FTMTP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","IRD"],"gpt_icon":0},{"id":"2566912810","title":"Opus Genetics Inc. Files Initial Beneficial Ownership Statement for CFO Robert E. Gagnon","url":"https://stock-news.laohu8.com/highlight/detail?id=2566912810","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566912810?lang=en_us&edition=fundamental","pubTime":"2025-09-12 05:58","pubTimestamp":1757627934,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc. has filed an initial statement of beneficial ownership with the United States Securities and Exchange Commission. The filing lists Robert E. Gagnon as the beneficial owner, holding the position of Chief Financial Officer at the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL3YTFFf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4139","BK4007"],"gpt_icon":0},{"id":"2564371785","title":"Opus Genetics Announces Dosing of First Patient in Phase 3 Trial of Phentolamine Ophthalmic Solution for Night Vision Disturbances","url":"https://stock-news.laohu8.com/highlight/detail?id=2564371785","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564371785?lang=en_us&edition=fundamental","pubTime":"2025-09-04 20:01","pubTimestamp":1756987268,"startTime":"0","endTime":"0","summary":"Opus Genetics Announces Dosing of First Patient in Phase 3 Trial of Phentolamine Ophthalmic Solution for Night Vision Disturbances. Opus Genetics Inc., a clinical-stage biopharmaceutical company, has announced the dosing of the first patient in its pivotal Phase 3 clinical trial, LYNX-3. The study is evaluating Phentolamine Ophthalmic Solution 0.75% for treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision. This trial follows the positive topline results of the earlier LYNX-2 Phase 3 trial announced in June 2025. The LYNX-3 study, which is the second Phase 3 trial for this indication, is being conducted with Fast Track designation and under a Special Protocol Assessment from the U.S. Food and Drug Administration. Results from this ongoing trial are yet to be presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDLbCyNrr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4585","LU0314104364.USD","BK4007","IE00BKPKM429.USD","BK4588","IE00B3QW5Z07.USD","NDAQ","BK4112","LU2210150020.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","BK4139","IRD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2564714533","title":"Opus Genetics Doses First Patient in Pivotal Lynx-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2564714533","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564714533?lang=en_us&edition=fundamental","pubTime":"2025-09-04 20:00","pubTimestamp":1756987203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nTUAVCN9R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","IRD"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":74,"code":"91000000","status":"200"}]}}